Cardiomyopathy

Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Efficacy and Safety of ICD Implantation in the Elderly

Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal standard of care
Sponsor:   Department of Veterans Affairs
Not yet recruiting - verified April 2014

Telemedicine Technology Demonstration Project for Heart Failure

Condition:   Heart Failure
Intervention:   Other: Telemedicine
Sponsors:   Providence Health & Services;   Verizon Wireless
Recruiting - verified April 2014

Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction

Conditions:   Heart Failure;   Preserved Ejection Fraction
Interventions:   Drug: Isosorbide Mononitrate;   Drug: Placebo
Sponsor:   Duke University
Recruiting - verified January 2014

Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease

Condition:   Inherited Mitochondrial Disease, Including Leigh Syndrome
Intervention:   Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
Sponsor:   Raptor Pharmaceuticals Inc.
Recruiting - verified March 2014

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Condition:   Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions:   Drug: Tafamidis;   Drug: Tafamidis;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

Conditions:   Heart Failure Congestive;   Ischemic Cardiomyopathy;   Non-ischemic Cardiomyopathy
Interventions:   Genetic: MYDICAR-single intracoronary infusion;   Genetic: Placebo; single intracoronary infusion
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Celladon Corporation
Recruiting - verified April 2014

Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside

Condition:   Non-ischemic Cardiomyopathy
Interventions:   Other: Resveratrol;   Other: Placebo
Sponsors:   St. Boniface General Hospital Research Centre;   Canadian Centre for Agri-food Research in Health and Medicine;   Agriculture and Agri-Food Canada;   Manitoba Medical Service Foundation
Not yet recruiting - verified April 2014

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Drug: Valsartan;   Drug: Placebo
Sponsors:   New England Research Institutes;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2013

Burden of Illness Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

Conditions:   Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP);   Transthyretin Cardiomyopathy (TTR-CM);   Familial Amyloid Cardiomyopathy;   Senile Systemic Amyloidosis (SSA)
Interventions:   Other: No drug;   Other: No drug
Sponsor:   Pfizer
Enrolling by invitation - verified April 2014

Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions:   Heart Failure;   Cardiac Failure;   Acute Decompensated Heart Failure (ADHF)
Interventions:   Device: Isolated veno-venous ultrafiltration (AQ);   Drug: IV Loop Diuretics (LD)
Sponsors:   Gambro Renal Products, Inc.;   Gambro UF Solutions, Inc.
Terminated - verified April 2014

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

Condition:   Cardiovascular Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Completed - verified March 2014

Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis

Conditions:   Sarcoidosis of the Heart;   Cardiomyopathy
Intervention:  
Sponsors:   Virginia Commonwealth University;   Stanford University;   Mount Sinai School of Medicine;   Weill Medical College of Cornell University;   The Cleveland Clinic
Enrolling by invitation - verified April 2014

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

Condition:   TTR-CM
Intervention:   Drug: tafamidis
Sponsor:   Pfizer
Active, not recruiting - verified April 2014

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions:   Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention:   Other: None. Observational Study.
Sponsor:   Pfizer
Recruiting - verified April 2014

Get CardioSmart

You're Invited